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Abstract
Background: High-Density Lipoprotein (HDL)-cholesterol, has been associated with breast cancer development, but
the association is under debate, and whether lipoprotein subfractions is associated with breast tumor characteristics
remains unclear.
Methods: Among 56 women with newly diagnosed invasive breast cancer stage I/II, aged 35–75 years, pre-surgery
overnight fasting serum concentrations of lipids were assessed, and body mass index (BMI) was measured. All breast
tumors were immunohistochemically examined in the surgical specimen. Serum metabolomics of lipoprotein
subfractions and their contents of cholesterol, free cholesterol, phospholipids, apolipoprotein-A1 and apolipoprotein-A2,
were assessed using nuclear magnetic resonance. Principal component analysis, partial least square analysis,
and uni- and multivariable linear regression models were used to study whether lipoprotein subfractions were associated
with breast cancer tumor characteristics.
Results: The breast cancer patients had following means: age at diagnosis: 55.1 years; BMI: 25.1 kg/m2; total-Cholesterol:
5.74 mmol/L; HDL-Cholesterol: 1.78 mmol/L; Low-Density Lipoprotein (LDL)-Cholesterol: 3.45 mmol/L; triglycerides:
1.18 mmol/L. The mean tumor size was 16.4 mm, and the mean Ki67 hotspot index was 26.5 %. Most (93 %) of the
patients had estrogen receptor (ER) positive tumors (≥1 % ER+), and 82 % had progesterone receptor (PgR)
positive tumors (≥10 % PgR+). Several HDL subfraction contents were strongly associated with PgR expression:
Apolipoprotein-A1 (β 0.46, CI 0.22–0.69, p < 0.001), HDL cholesterol (β 0.95, CI 0.51–1.39, p < 0.001), HDL free cholesterol
(β 2.88, CI 1.28–4.48, p = 0.001), HDL phospholipids (β 0.70, CI 0.36–1.04, p < 0.001). Similar results were observed for the
subfractions of HDL1-3. We observed inverse associations between HDL phospholipids and Ki67 (β -0.25, p = 0.008), and
in particular between HDL1’s contents of cholesterol, phospholipids, apolipoprotein-A1, apolipoprotein-A2 and Ki67. No
association was observed between lipoproteins and ER expression.
Conclusion: Our findings hypothesize associations between different lipoprotein subfractions, and PgR expression, and
Ki 67 % in breast tumors. These findings may have clinical implications, but require confirmation in larger studies.
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Background
High-density lipoprotein (HDL), an important mediator of
lipid homeostasis, transports and stores cholesterol for ex-
cretion [1], and cholesterol is a precursor of estrogen and
progesterone [2], key factors in breast cancer development
[3]. Moreover, increased levels of HDL cholesterol have
been inversely associated with breast cancer development
[4, 5], while increased levels of low density lipoprotein
(LDL) cholesterol has been positively associated with
breast tumor size, grade and proliferation [6]. HDL and
apolipoprotein-A1 (Apo-A1) have also been shown to
facilitate cholesterol efflux from white blood cells, thus
decreasing the cellular lipid raft abundance [7, 8]. Whether
HDL subfractions are associated with breast tumor charac-
teristics is, however, less known.
Interestingly, low levels of HDL have been associated
with increased levels of low-grade inflammation and
proinflammatory cytokines [9–13], which in turn induce
higher local estradiol levels and breast cell proliferation
[14, 15]. We have recently observed that HDL-C levels,
either alone or in combination with high levels of estrogen
or progesterone, were associated with mammographic
density phenotypes [16]. Moreover, lipid molecules have
been shown to influence inflammation [9, 10], one of the
hallmarks in cancer and breast cancer development [17]
and prognosis [18], and elevated biomarkers of inflamma-
tion are associated with reduced survival among breast
cancer patients. Notably, smaller and more dense HDL-
particles may display different anti-inflammatory proper-
ties compared to larger HDL-particles [19], and may link
lipoprotein subfractions to breast cancer development and
breast tissue composition. Additionally, hypercholesterol-
emia, strongly associated with low HDL-C levels, may
induce angiogenesis [20]. Thus, there is a biological plausi-
bility for an association between lipoproteins, estrogen,
progesterone and breast cancer development and progno-
sis [4, 6, 21]. To our knowledge, studies evaluating sub-
fractions of lipoproteins have been limited to patients with
cardiovascular disease, and have not yet included cancer
patients [22–26].
The lipoprotein particle distributions have a high poten-
tial for improving the diagnostics of metabolic disorders
[27], of potential importance for breast cancer develop-
ment and treatment, and in particular among those with
other comorbid conditions e.g., diabetes [28, 29]. Detect-
ing metabolites downstream of gene- and protein activity,
that influence endogenous metabolomic processes of
potential importance for breast cancer development, has
been enabled by emerging metabolomic profiling tech-
nologies. Magnetic resonance (MR) metabolomics has
become one of the key methods in this research area [30].
Lipidomics refers to the use of analytical methods to iden-
tify and quantify lipid components in a biological matrix,
such as biological fluids [31]. Recently very low density
lipoprotein (VLDL) was associated with transport capacity
of lipids to cancer cells [32]. Thus, to study lipidomics in
more detail in relation to breast cancer development, we
questioned whether a patient’s lipid profile, as visualized
by the explorative lipoprotein subfraction method, may be
associated with the histopathological characteristics of
breast tumors [33, 34].
Thus, the main aim of this explorative, hypothesis generat-
ing study was to investigate the association between serum
metabolomic lipoprotein subfractions and their contents of
cholesterol, free cholesterol, phospholipids, apolipoprotein-
A1 and apolipoprotein-A2, using nuclear magnetic reson-
ance (NMR), and different breast tumor characteristics.
Methods
Participants and study design
A total of 60 breast cancer patients, aged 35–75 years,
with newly diagnosed DCIS grade 3 and invasive breast
cancer (histologically verified), stages I-II, were included
in a clinical breast cancer study during 2011–2013 at the
Cancer Center, Oslo University Hospital (OUS), St. Olavs
Hospital, Trondheim, and Vestre Viken HF, Drammen.
Women with known severe illnesses (i.e., heart disease,
diabetes), were excluded. In the present study only women
with histological verified invasive breast cancers were in-
cluded: four women with DCIS grade 3 were excluded,
thus 56 women diagnosed with invasive breast cancer
were included in the present study.
Assessment of clinical variables
Baseline patient characteristics, clinical data, and study
measurements were assessed before treatment (surgery,
radiation, chemotherapy) by trained study nurses and
senior oncologists. Anthropometric measurements were
performed with participants wearing light clothing and no
footwear. Height was measured to the nearest 0.5 cm, and
weight to the nearest 0.1 kg on an electronic scale, and
BMI (kg/m2) was calculated. Blood pressure (BP) was
measured three times (Dinamap-Pro Care 300), with the
patient sitting in a resting position. The second measure-
ments were used in the analysis.
Blood samples were drawn after overnight fasting. Total
cholesterol, HDL-C, and triglycerides were measured in
fresh sera at the Department of Clinical Chemistry, OUS,
Ullevål (Roche Diagnostics/Cobas Integra 800- Cobas
8000, Mannheim, Germany, www.roche.com). Cholesterol
was determined enzymatically using cholesterol esterase
and cholesterol oxidase, intra-assay coefficient of variance
(CV) was 6 % and inter assay CV was 3 %. HDL-C was
quantified by a direct assay using polyethylene glycolmo-
dified enzymes and dextran sulphate. HDL-C’s intra assay
CV was 7 %, and inter assay CV was 4 %. Serum triglycer-
ides were assayed by enzymatic hydrolysis with lipase, and
had an intra-assay CV of 21 %, and inter-assay CV of
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4 %. LDL-C was calculated using Friedewalds formula.
Apolipoproteins A and B were measured using Cobas
c501, (Roche diagnostics) and had intra-/inter-assay
CVs of 7 %/4 % and 7 %/5 %, respectively.
Tumor characteristics
All breast cancer surgical specimens were histologi-
cally and immunohistochemically examined. Tumors
were classified according to invasive histological type
(ductal, lobular, others), histological grade (1-3), and
tumor diameter was measured both macro- and micro-
scopically (mm). Lymph nodes were investigated to de-
tect macro- or micro-metastasis, using sentinel lymph
node (SN) biopsy technique for identifying axillary
metastases.
Tumors were routinely investigated with immuno-
histochemistry for selected markers: estrogen receptor
(ER), progesterone receptor (PgR), human epidermal
growth factor receptor 2 (HER2), and tumor cell pro-
liferation (Ki67 hotspot index). The following anti-
bodies were used: ER (clone SP1), PgR (clone 1E2),
HER2 (Pathway anti-HER 2 kit, clone 4B5), and Ki67
(MIB1 antibody), all from Ventana, Roche Diagnostics
(Oslo, Norway), except MIB1 which was provided by
Dako (Oslo, Norway). Primary antibodies were visual-
ized with Ultraview detection kit from Roche. ER, PgR
and HER2 expression were measured according to the
international guidelines (ASCO/College of American
Pathologists [CAP]). Hormone receptor expression
was given as the average percent of positive cells in
the tumor. ER positive status was defined as ≥1 % ER-
expressing tumor cells, and PgR positive status as ≥10 %
PgR-expressing tumor cells. PgR expression may vary be-
tween different areas of the tumor as shown in Fig. 1 [35],
and for 12 of the tumors the PgR positive fraction was
given as above or below 50 %. These 12 tumors were
set to PgR 50 % +. Immunohistochemic quantification
of PgR is a reliable semiquantitative method used in
clinical practice, but do have some limitations, but
Immunohistochemic quantification of PgR has repeat-
edly, and recently been reported as a prognostic
marker [36]. Tumors were investigated with HER2
Dual SISH in situ hybridization kit in order to deter-
mine HER2 status. The percentage of expression of
Ki67 positive tumor cells was determined according to
national and international guidelines [37, 38]. The Ki67
positive fraction was determined by counting at least
500 tumor cells in three representative high-power (x40
objective) fields in the most proliferative area of the
tumor (“hot spot”), which was usually in the periphery.
Ki67 score is defined as the percentage of positively
stained cells undergoing active mitosis among the total
number of malignant cells [37].
Metabolic/lipidomic profiling- Magnetic resonance (MR)
experiments
Venous fasting blood samples were collected in serum-
tubes with no additives. The serum samples were stored
at − 80 °C, until the time of metabolic profiling. The
serum samples were slowly thawed at 4 °C. Aliquots of
150 μL were mixed with equal amounts of buffer solu-
tion and transferred to high-quality 3 mm MR tubes as
described elsewhere [30].
The MR spectra were acquired using a Bruker Avance III
600 MHz/54 mm US-Plus (Bruker Biospin, Rheinstetten,
Germany) operating at 600 MHz for proton (1H), equipped
with a QCI cryoprobe. All spectra were recorded in an
automatic fashion using a Bruker SampleJet and the ICON-
NMR software (Bruker Biospin). Proton spectra were
obtained at a constant temperature of 310 K (37 °C) using
[1] a standard nuclear overhauser effect spectroscopy
(NOESY) pulse sequence (Bruker: noesygppr1d) and [2] a
Carr-Purcell-Meiboom-Gill (CPMG) pulse sequence
with presaturation during the relaxation delay (Bruker:
cpmgpr1d) to achieve water suppression, and to facilitate
the detection of low-molecular-weight species by avoiding
the large overlapped signals derived from large molecules,
such as proteins and lipids. Measurement and processing
were done in full automation using Bruker standard auto-
mation programs controlled by ICON-NMR (along with
TopSpin). Chemical shift was calibrated to the middle of
the alanine peaks at 1.50 ppm.
MR spectra - MR based lipoprotein subclass analysis
Pre-processing of data was performed with MATLAB
(Version 8.0.0.783 (R2012b); The Math Works, Natick,
MA). The spectral region between 4.5 and 5.0 ppm was
excluded to remove variation in water suppression effi-
ciency. Spectra were normalized by setting the total
spectral area to a constant value (=1) for all spectra to
minimize possible differences in concentration between
the samples.
Calculation of lipoprotein related parameters from
the plasma 1H NMR data was done at Bruker BioSpin
GmbH Rheinstetten, Germany. For this, a regression
model was applied which was developed by Bruker for
NMR based lipoprotein subclass analysis [39], imple-
menting a similar approach as established by Petersen
et al. [40]. In brief, this approach is based on partial
least squares modelling on a training data set which
utilizes a combination of ultracentrifugation values on
lipoprotein subclasses and 1H NMR spectra available
for each plasma sample in a method training step.
Model performance with respect to prediction quality
and reliability is validated using cross-validation and
test-set validation as employed e.g., in [41] and [27].
Once established, the resulting regression model can
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be used to predict lipoprotein related analytes directly
from the 1H-NMR spectra of new plasma or serum
samples not part of the training set, without further
need for ultra-centrifugation. Using such a model,
information extracted from the NMR data included
the plasma content of very-low density lipoprotein
(VLDL: <1.006 kg/l), intermediar low-density lipopro-
tein (ILDL: 1.006–1.019 kg/l), low-density lipoprotein
(LDL: 1.019–1.063 kg/l), and high-density lipoprotein
(HDL: 1.063–1.210 kg/l), as well as six subclasses of
VLDL (VLDL-1, VLDL-2, VLDL-3, VLDL-4, VLDL-5,
VLDL-6), six subclasses of LDL (LDL-1, LDL-2, LDL-3,
LDL-4, LDL-5, LDL-6) and four subclasses of HDL
(HDL-1, HDL-2, HDL-3, HDL-4). Subclasses were
sorted according to increasing density and decreasing
size in ascending order, respectively. Compositional
information of main- and subclasses consists of the
lipoprotein content concentrations of lipids, i.e., choles-
terol, free cholesterol, phospholipids and triglycerides
and apolipoproteins; Apo-A1, Apo-A2 and Apo-B.
Model performance is comparable to the results re-
ported in [27], as indicated by key model performance
parameters summarized in Fig. 2 [39].
Statistical methods
Descriptive statistics were used to describe the patient
characteristics, including: age, anthropometric measure-
ments, serum lipids (cholesterol, HDL-cholesterol, LDL-
cholesterol, triglycerides, apolipoproteins) and tumor
characteristics (tumor size, number of metastatic lymph
nodes, estrogen and progesterone receptor, HER-2, and
Ki-67 hot spot index). Continuous variables were
assessed by means, standard deviations (SD), numbers
and percentages, and the Chi-square test was used on
categorical variables. Descriptive statistics of all lipopro-
tein subfractions were evaluated by means and SDs.
Pearson’ correlations of the breast cancer tumor charac-
teristic, and serum lipid variables were estimated and
tested for significance. All lipoprotein variables were ap-
proximately normally distributed, hence no transforma-
tions were needed.
Based on plausible biological mechanisms hypothe-
sized between lipid fractions and breast cancer develop-
ment and prognosis, and previous works on MR
metabolomics [42], we decided to use Principal Compo-
nents Analysis (PCA) and Partial Least Square analysis
(PLS) [42]. These statistical methods were chosen to in-
vestigate associations between lipoprotein subfractions
and breast cancer tumor characteristics, while address-
ing the problem of multiple testing in our data with 56
samples and 105 different lipoprotein subfractions. The
Principal Component Analysis (PCA) and Partial Least
Square analysis (PLS) have proven powerful for dimen-
sion reduction and description of trends in large data
sets. By using Principal Component Analysis (PCA), we
ended up with eight components, and these eight com-
ponents explained approximately 97 % of the variance of
the 105 subfractions. In components with observed asso-
ciations, we identified the specific lipoproteins with the
highest scores. We then performed both uni- and mul-
tivariable linear regression between the high score li-
poproteins and breast tumor characteristics. Potential
confounding factors influencing tumor characteristics
were tested in regression models, including: age (continu-
ous), BMI (continuous), menopausal status (categorical),
statin use (categorical), birth of children (categorical, yes/
no), current smoking habits (categorical, yes/no), and pre-
vious oral contraceptive use (categorical, yes/no). Age,
BMI and menopausal status were included as covariates in
the final models.
To evaluate the results observed between lipoproteins
and breast tumor characteristics using Principal Com-
ponent Analysis (PCA), we also performed Partial
Least Square analysis (PLS), for which only three com-
ponents were needed. All p-values were two-tailed and
considered significant if p < 0.05. The descriptive,
correlation, principal component, and regression ana-
lyses were conducted with SPSS version 21.0 (IBM
Corp. Armonk, NY, USA), and the partial least square
Fig. 1 Different levels of Progesterone receptor status; 0 %, 20 %, 100 %
and intratumoral heterogeneity
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analyses using the library of the R statistical package
(http://cran.r-project.org/).
Ethical considerations
All participants signed an informed consent form. The
study was approved by the Norwegian Regional Committee
for Medical Research Ethics.
Results
The participating breast cancer patients had the following
means: 55.1 years at diagnosis, BMI of 25.1 kg/m2, total
cholesterol of 5.74 mmol/L, HDL-cholesterol of
1.78 mmol/L, LDL-cholesterol of 3.45 mmol/L, and Tri-
glycerides of 1.18 mmol/L. The breast tumor size was on
average 16.4 mm, and the mean Ki67 hotspot index was
26.5 %. 93 % of the breast tumors were ER+, 82 % were
PgR+, and 7 % of the patients had hormone receptor
negative disease (Table 1). BMI was not correlated with
any of the tumor characteristics, but positively correlated
with serum triglycerides, and inversely correlated with
HDL-C (results not presented). The concentrations by
means of the lipoprotein subfractions with lipid/lipopro-
tein contents are shown in Table 2.
We observed positive correlations between tumor char-
acteristics and serum lipids. The continuous percentage
PgR expression (Fig. 2) was inversely correlated with tumor
grade and Ki67 hotspot index (Grade: correlation coeffi-
cient − 0.508, p < 0.001. Ki67: correlation coefficient −
0.577, p < 0.001) (Additional file 1: Table S1). Furthermore,
we found positive correlations between PgR expression
and both HDL and Apo-A (Additional file 1: Table S1).
By using Principal Component Analysis (PCA), in
combination with uni- and multivariable linear regres-
sion analyses, total plasma apolipoprotein-A1 and the
contents of cholesterol, free cholesterol, apolipoprotein-
A1, apolipoprotein-A2, and phospholipids of HDL, HDL-1,
HDL-2 and HDL-3, were associated with tumor PgR ex-
pression (Table 3). When performing multivariable linear
regression, the following associations were found be-
tween PgR expression and lipids: total plasma Apo-A1
(β 0.46, p < 0.001), HDL-cholesterol (β 0.95, p < 0.001)
(Table 3 and Fig. 3). We found no associations between
the smaller and denser HDL-4 and PgR expression, and
we found no association between any of the lipopro-
teins and ER status. In addition, we found inverse asso-
ciations between HDL phospholipids and Ki67 (β -0.25,
p = 0.008), and in particular with HDL1 and the con-
tents of cholesterol, phospholipids, apolipoprotein-A1
and apolipoprotein-A2 and Ki67 (Table 3). The esti-
mated β-coefficients (the linear gradient slope), and
each unit increase of the lipoproteins were associated
with a higher percentage level of PgR expression. These
associations were similar in both the uni- and multivar-
iable analyses (Table 3). The same analyses were also
run by excluding the hormone negative cancers, with
attenuated results (Additional file 2: Table S2).
We observed similar associations between lipopro-
teins and PgR expression in the Partial Least Square
analysis (PLS) (Table 4); total plasma Apo-A1 (β 0.13,
p = 0.002), HDL cholesterol (β 0.09, p < 0.001), but in
addition it showed inverse trends between ILDL and
PgR expression (p = 0.062), and between VLDL and
PgR expression (p = 0.056), respectively (Table 4). Fur-
thermore, we also observed an inverse association
between total plasma triglycerides and tumor grade
(Table 4). No association was found between the
smaller and denser HDL4 and PgR, and no association
was found between lipoproteins and ER expression in
breast tumors.
Table 1 Descriptive statistics of the breast cancer patients by
means and standard deviations (SD), n = 56
Characteristics Mean (min.-max.) SD
Age at diagnosis, years 55.1 (38–69) 7.89
Education, years 15.8 (8–24) 3.47
Postmenopausal, no (%) 38 (68 %)
Systolic BP, mmHg 132 (87–184) 22.9
Diastolic BP, mmHg 77.4 (58–108) 11.9
Height, cm 167 (155–181) 5.97
Weight, kg 70.5 (49–97) 11.6
BMI, kg/m2 25.1 (20.0–33.2) 3.48
Statin use, no (%) 3 (5 %)
Serum lipoproteins
Cholesterol, mmol/L 5.74 (4.00–8.00) 1.00
HDL-cholesterol, mmol/L 1.78 (1.00–3.00) 0.49
LDL-cholesterol, mmol/L 3.45 (1.31–5.49) 0.98
Triglycerides, mmol/L 1.18 (0–3) 0.59
Apolipoprotein-A, mmol/L 1.67 (1–3) 0.29
Apolipoprotein-B, mmol/L 1.04 (0–2) 0.27
Tumor characteristics
Tumor diameter, mm 16.4 (4–40) 8.52
Grade 1–3 1.96 (1–3) 0.71
Ki-67 hotspot, % 26.5 (1–81) 21.8
Nodal metastasis, no 0,75 (0–11) 2.13
ER positive, no (%) 52 (93 %)
ER percent 88,1 (0–100) 26.9
PgR positive, no (%) 46 (82 %)
PgR percent 64,2 (0–100) 36.8
Hormone receptor negative, no (%) 4 (7 %)
HER2 positive, no (%) 3 (5 %)
Abbreviations: BP blood pressure, BMI body mass index, ER estrogen receptor,
HER2 human epidermal growth factor 2, HDL high-density lipoprotein, LDL
low-density lipoprotein, PgR progesterone receptor, Ki 67 antigen Ki-67. ER
positive when ≥ 1 %. PgR positive when ≥ 10 %
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Discussion
In the present explorative, and hypothesis generating
study, we observed strong positive associations of metabo-
lomic lipoprotein subfractions Apo-A1, HDL, and larger
HDL subfractions’ contents of cholesterol, free cholesterol,
phospholipids, and apolipoprotein-A1 with tumor PgR ex-
pression. No associations were observed between the
smaller and denser HDL-4 and PgR expression. Further-
more, we observed an inverse association between the
lipoprotein subfractions HDL1 and tumor cell prolifera-
tion, Ki67 index, and that very low-density lipoprotein
(VLDL) was positively associated with nodal metastasis.
To our knowledge, this is the first study to investigate
whether various lipoprotein subfractions are associated
with breast cancer tumor characteristics. However, our re-
sults are supported by several observational studies linking
cholesterol and lipoproteins to breast cancer development
[4, 5] and survival [43]. Studies have also observed that
there are distinct differences in the lipid metabolomics
profiles comparing early and metastatic breast cancer [44].
The cholesterol metabolite, 27-OH cholesterol, has been
observed to induce breast cancer cell proliferation and
metastasis in hormone receptor positive cell lines, and 27-
OH cholesterol is hypothesized to be one of the links
between obesity and breast cancer [45, 46]. These findings
support that also the type of cholesterol metabolite may
play a role in breast cancer risk and prognosis.
The associations between lipoproteins and breast cancer
development and prognosis may vary by type of lipopro-
teins, as we observed a positive association between the
larger HDLs and PgR expression in breast tumors, but no
associations between the smaller and more dense HDL4
and PgR expression. Recently, PgR expression < 20 % has
been associated with poor prognosis [36, 47, 48], and
patients initially diagnosed with PgR+ breast cancer had a
worse outcome if recurrence of disease was PgR− [49].
Moreover, the TransAttack study showed that the lowest
PgR percentage quartile had an unfavourable prognosis as
compared to the highest quartile [50]. A proposed mech-
anism is that ligand activation of PgR induces PTEN ex-
pression and thereby inhibits the PI3K/AKT pathway [51].
In addition, PgR associates with ERα resulting in an
increased anti-proliferative effect by a unique gene expres-
sion program that is associated with good clinical out-
come. Moreover, copy number loss of the PGR gene is a
common feature in ERα + breast cancers, and may explain
lower PgR levels in a subset of cases [52]. These observa-
tions partly support our findings, and hypothesize that an
Table 2 The lipoprotein subfractions and their contents of lipids and lipoproteins in means and standard deviations (SD) by Nuclear
Magnetic Resonance analyses
Triglycerides Cholesterol Free cholesterol Phospholipids Apo-A1 Apo-A2 Apo-B
Total plasma, mg/dL 125 (57.2) 245 (58.9) 77.7 (17.8) − 188 (36.7) 40.5 (9.53) 84.3 (23.1)
VLDL, mg/dL 70.1 (47.3) 16.4 (12.6) 8.81 (5.24) 18.9 (12.4) − − 5.29 (3.38)
VLDL1, mg/dL 40.5 (20.4) 5.85 (4.05) 2.33 (1.53) 7.25 (4.99) − − −
VLDL2, mg/dL 11.6 (8.88) 2.94 (2.21) 0.96 (0.84) 3.77 (2.81) − − −
VLDL3, mg/dL 7.80 (7.36) 2.23 (2.40) 1.19 (0.88) 4.20 (3.02) − − −
VLDL4, mg/dL 6.14 (4.97) 3.01 (2.93) 1.34 (1.32) 4.18 (3.31) − − −
VLDL5, mg/dL 1.86 (0.84) 1.12 (0.33) 0.46 (0.25) 1.70 (1.09) − − −
VLDL6, mg/dL 3.65 (1.41) 0.15 (0.01) 0.02 (0.05) 0.40 (0.03) − − −
ILDL, mg/dL 12.2 (7.23) 9.69 (5.65) 3.29 (1.64) 7.37 (3.44) − − 3.67 (1.52)
LDL, mg/dL 24.8 (5.99) 142 (45.5) 48.4 (13.6) 82.2 (23.1) − − 67.7 (19.8)
LDL1, mg/dL 7.32 (2.77) 24.2 (7.92) 8.80 (2.82) 9.66 (4.33) − − 9.74 (2.86)
LDL2, mg/dL 2.28 (0.77) 20.9 (8.44) 6.87 (2.94) 12.5 (4.71) − − 7.96 (3.08)
LDL3, mg/dL 2.43 (0.86) 25.4 (9.08) 10.1 (2.95) 14.4 (4.85) − − 10.6 (3.44)
LDL4, mg/dL 3.93 (1.24) 35.6 (11.6) 11.5 (3.14) 18.5 (6.43) − − 11.8 (3.16)
LDL5, mg/dL 2.68 (1.36) 26.0 (10.4) 9.65 (2.98) 14.5 (5.52) − − 12.2 (4.85)
LDL6, mg/dL 4.94 (1.59) 27.8 (12.1) 8.42 (3.34) 16.1 (6.20) − − 15.8 (6.49)
HDL, mg/dL 10.2 (4.60) 72.7 (19.4) 23.2 (5.56) 104 (25.3) 146 (32.5) 38.2 (8.74) −
HDL1, mg/dL 4.39 (2.69) 21.3 (12.0) 9.22 (3.63) 28.3 (14.6) 27.3 (17.5) 3.36 (2.04) −
HDL2, mg/dL 1.11 (0.88) 9.65 (3.42) 3.52 (1.23) 16.1 (5.78) 15.7 (6.76) 3.19 (1.68) −
HDL3, mg/dL 1.96 (0.87) 13.8 (3.68) 4.63 (1.09) 22.5 (5.81) 31.1 (7.09) 7.52 (2.39) −
HDL4, mg/dL 4.34 (1.17) 26.5 (5.16) 7.98 (1.51) 35.0 (5.57) 74.6 (10.8) 19.5 (4.72) −
Abbreviations: Apo apolipoprotein, HDL high-density lipoprotein, ILDL intermediar low-density lipoprotein, LDL low-density lipoprotein, VLDL very
low-density lipoprotein
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association between the contents of lipoproteins and PgR
expression and Ki67 may be useful in the identification of
follow-up of high risk groups.
In the present study, we observed an inverse association
between HDL1 and Ki67 hot spot index. Furthermore, we
observed that very low-density lipoprotein (VLDL) was
positively associated with nodal metastasis, and inversely
associated with PgR expression. Thus, type of lipoprotein
subfractions may be associated with several breast tumor
characteristics, and not only PgR expression. These find-
ings are partly supported by others, as high LDL levels
were positively associated with breast tumor size, and
Ki67 index, and also showed a trend towards more lymph
node metastasis [6].
In an NMR study, high lipid spectra was associated
with inflammation [53], supporting that metabolomic
lipoprotein subfractions may play a role also in relation
to inflammatory factors and pathways of importance
for breast cancer development. Our observation that
very low-density lipoprotein (VLDL) was positively as-
sociated with nodal metastasis, may be explained by the
association between dyslipidaemia and vascular endothelial
growth factor C (VEGF C) [54], as VEGF C promote nodal
metastasis in combination with inflammatory cascades me-
diated particularly through tumor associated macrophages
[55]. In addition, VLDL transports cholesterols, oxysterols
and triglycerides from the liver to various tissues, and rap-
idly proliferating cancer cells require a constant supply of
lipids for membrane biogenesis, protein modifications and
steroid hormone production [32].
Studies suggest that the contents of lipoproteins may
affect the development of several chronic diseases, and
Fig. 2 The relationship between serum NMR spectra and the lipoprotein subfractions. a Representative 1H NMR spectra from two individual
breast cancer patients. b The two main lipid peaks represent methyl and methylene proton signals from lipid moieties within the lipoprotein
particles. Minor differences in distribution of lipoprotein subfractions result in distinct line shape differences. c By regression-based modelling of
the relationship between lipid signal line shape and lipoprotein subfractions, lipoprotein subfractions can be determined in new serum samples
based on the 1H NMR spectrum
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Table 3 Principal Component analysis (PCA); the association between tumor characteristics and lipoprotein subfractions by NMR
Univariable Multivariable
Tumor characteristics β-coefficient 95 % CI p-value β-coefficient 95 % CI p-value
Progesterone receptor (%)
Total plasma Apolipoprotein A1, mg/dL 0.41 (0.17, 0.65) 0.001 0.46 (0.22, 0.69) <0.001
HDL Cholesterol, mg/dL 0.86 (0.41, 1.31) <0.001 0.95 (0.51, 1.39) <0.001
HDL Free Cholesterol, mg/dL 2.64 (1.03, 4.26) 0.002 2.88 (1.28, 4.48) 0.001
HDL Phospholipids, mg/dL 0.66 (0.31, 1.01) <0.001 0.70 (0.36, 1.04) <0.001
HDL Apolipoprotein A1, mg/dL 0.50 (0.22, 0.78) 0.001 0.56 (0.29, 0.83) <0.001
HDL Apolipoprotein A2, mg/dL 1.16 (0.06, 2.26) 0.040 1.53 (0.48, 2.58) 0.005
HDL1 Phospholipids, mg/dL 1.02 (0.39, 1.64) 0.002 0.96 (0.35, 1.57) 0.003
HDL1Cholesterol, mg/dL 1.20 (0.43, 1.97) 0.003 1.15 (0.41, 1.89) 0.003
HDL1Free Cholesterol, mg/dL 3.36 (0.80, 5.92) 0.011 3.44 (0.95, 5.93) 0.008
HDL1 Apolipoprotein A1, mg/dL 0.81 (0.29, 1.34) 0.003 0.76 (0.25, 1.27) 0.004
HDL1 Apolipoprotein A2, mg/dL 6.75 (2.20, 11.3) 0.004 6.39 (2.08, 10.7) 0.004
HDL2 Phospholipids, mg/dL 2.54 (0.95, 4.13) 0.002 2.30 (0.61, 3.98) 0.008
HDL2 Cholesterol, mg/dL 3.87 (1.19, 6.54) 0.005 4.42 (1.70, 7.15) 0.002
HDL2 Free Cholesterol, mg/dL 10.9 (3.48, 18.4) 0.005 11.6 (4.39, 18.9) 0.002
HDL2 Apolipoprotein A2, mg/dL 6.01 (0.26, 11.8) 0.041 6.74 (1.26, 12.2) 0.017
HDL2 Apolipoprotein A1, mg/dL 2.15 (0.79, 3.51) 0.003 2.29 (0.95, 3.63) 0.001
HDL3 Phospholipids, mg/dL 2.53 (0.95, 4.11) 0.002 2.88 (1.32, 4.43) 0.001
HDL3 Cholesterol, mg/dL 3.75 (1.28, 6.22) 0.004 4.44 (1.94, 6.95) 0.001
HDL3 Free Cholesterol, mg/dL 11.48 (3.06, 19.9) 0.008 13.5 (5.05, 22.0) 0.002
HDL3 Apolipoprotein A1, mg/dL 2.04 (0.73, 3.34) 0.003 2.38 (1.09, 3.66) 0.001
VLDL4 Cholesterol, mg/dL −3.59 (−6.88,−0.31) 0.033 −3.76 (−7.16,−0.37) 0.031
VLDL 4 Free Cholesterol, mg/dL −7.59 (−14.9, −0.27) 0.043 −7.75 (−15.3,−0.20) 0.044
Ki 67, %
HDL Phospholipids, mg/dL −0.25 (−0.47, −0.02) 0.033 −0.31 (−0.53,−0.08) 0.008
HDL1 Cholesterol, mg/dL −0.48 (−0.96, −0.01) 0.048 −0.54 (−1.00,−0.07) 0.024
HDL1 Phospholipids, mg/dL −0.40 (−0.80,−0.01) 0.043 −0.46 (−0.84,−0.08) 0.020
HDL1 Apolipoprotein A1, mg/dL −0.31 (−0.64, 0.02) 0.066 −0.35 (−0.67,−0.03) 0.032
HDL1 Apolipoprotein A2, mg/dL −3.23 (−6.01,−0.45) 0.024 −3.28 (−5.94,−0.62) 0.017
HDL2 Phospholipids, mg/dL −1.08 (−2.06,−0.09) 0.033 −1.30 (−2.28,−0.31) 0.011
Nodal metastasis
VLDL1 Triglycerides, mg/dL 0.03 (0.00, 0.06) 0.033 0.03 (0.00, 0.07) 0.036
VLDL1 Free Cholesterol, mg/dL 0.38 (0.01, 0.74) 0.045 0.41 (−0.01, 0.83) 0.057
LDL2 Free Cholesterol, mg/dL −0.19 (−0.38,−0.00) 0.049 −0.17 (−0.37, 0.02) 0.084
LDL3 Free Cholesterol, mg/dL −0.21 (−0.40,−0.03) 0.026 −0.20 (−0.40,−0.01) 0.049
Estrogen receptor (%) No significant associations
Grade 1–3
Tumor size, mm
Univariable and multivariable linear regression model. Multivariable model adjusted for age, BMI and menopausal status. 95 % Confidence Interval. Significance
level p < 0.05
Abbreviations: HDL high-density lipoprotein, VLDL very-low-density lipoprotein, LDL low-density lipoprotein
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that the lipoprotein distribution may be of importance
particularly in metabolic disorders [27]. A lipid reduced
growth environment may attenuate cancer cell prolifera-
tion [32], and this knowledge may be helpful in design-
ing new anti-tumor strategies [32]. Thus, it is important
to further elucidate the different lipoproteins carrying
various lipids, both in relation to size and density of the
various lipoproteins. Larger HDL particles have been
observed to reduce atherosclerotic development, and
smaller HDL-particles are associated with obesity and
metabolic syndrome [56]. These observations suggest
shared biological mechanisms in the development of
some chronic diseases. Recently, a difference between
HDL-levels in breast cancer patients with, and without
diabetes, was observed [29, 57]. HDL in diabetic breast
cancer patients in contrast to nondiabetic patients may
promote migration and invasion in both ER/PgR positive
and PgR/ER receptor negative breast cancer through ERK
and p38 MAPK pathways [29, 57]. Moreover, obese young
breast cancer patients were found to have larger tumors,
higher grade, and were more often ER negative and PgR
negative [58], and the oxysterol, 27OH-Cholesterol, is as-
sociated with hormone receptor positive breast cancer cell
proliferation [45]. These findings suggest that an asso-
ciation between type of lipoproteins and breast tumor
characteristics may vary among breast cancer patients,
depending on comorbidity (diabetes, obesity), age and
menopausal status. In addition, previous studies have shown
that the tumor expression of hydroxyl-methylglutaryl-coen-
zyme-A (HMG-CoA) reductase, the rate limiting enzyme in
the cholesterol production, is associated with less aggressive
tumor profiles, e.g., lower histological grade, estrogen and
progesterone receptor positivity [28]. Previous studies have
shown that increased lipid NMR signals have been
attributed to inflammatory response in cancer [59].
Thus, several plausible biological mechanisms linking
lipids and the contents of lipoproteins to breast cancer
development support our findings. Low levels of HDL-C
have been observed to stimulate inflammation through
activation of the innate immunity [9, 11, 60], and to
stimulate the production of neutrophils and proinflamma-
tory macrophages inducing high levels of pro-inflammatory
cytokines [10, 61, 62], higher local hormone levels and cel-
lular proliferation in the breast [14, 63]. In addition, the
HDL protein content [24, 26, 64] is also linked to inflam-
mation. Of note, HDL and Apo-A1 may facilitate monocyte
cholesterol efflux and thereby decrease cholesterol lipid
rafts [8]. Moreover, an appropriate level of both HDL and
Apo-A1 may down-regulate leukocyte activation [8]. Re-
cently Apo-A1 was found to be down regulated in breast
cancer patients [65]. In addition, oxidized LDL may trigger
inflammation and PI3K, and reduce intracellular PTEN in
human mammary epithelial cells [66].
All participating breast cancer patients were newly
diagnosed with invasive breast cancer, and overnight
fasting blood samples were drawn prior to surgery. The
Fig. 3 The multivariable linear association between lipoproteins and progesterone receptor status (%), adjusted for age, BMI and menopausal status
with 95 % confidence interval. a HDL cholesterol, b HDL Free cholesterol, c HDL phospholipids, d total Apo-A1, e HDL Apo-A1, f HDL2 Apo-A1
Flote et al. Lipids in Health and Disease  (2016) 15:56 Page 9 of 12
patients were informed about the breast cancer disease
1–5 days before blood sampling. Thus, any lifestyle
changes including e.g., changes in dietary habits influen-
cing their lipid profile, is less likely. Moreover, the par-
ticipating women had an average BMI of 25.1 kg/m2,
and BMI was inversely associated with HDL-C. Even
though BMI was not associated with any of the tumor
characteristics in this study, BMI has been shown to be
a prognostic marker [67], and our final multivariable
analysis included BMI as a covariate. The mean levels of
cholesterol, and triglyceride observed in the present study
are comparable with values observed among healthy
women [68]. Blood lipid levels tend to remain stable, unless
intensive intervention, such as lipid lowering medications,
has occurred [69]. Importantly, lipid lowering medications
were rarely used among our patients, and adjustments for
lipid lowering medications did not influence our results.
All clinical measurements were performed by trained
personnel using validated methods at the research unit at
the Oslo University hospital, Ullevål.
However, our study is explorative, and the study design
was cross-sectional, and therefore we cannot establish
cause-and-effect, and our results should thus be interpreted
as explorative and hypothesis generating. Our sample size
was small, and in combination with multiple testing, there
is a risk of false positive results. In order to address these
challenges, we used the robust statistical methods Partial
Least Square analysis (PLS) and Principal Component
Analysis (PCA) to support the results. The present method,
developed and used to divide lipoproteins into 105 subfrac-
tions in breast cancer patients, is novel, and need to be vali-
dated in other studies, and importantly, later studies should
compare results among breast cancer patients with healthy
women. We also note that the expression of PgR in breast
cancer tumors can vary across the area of the tumor [30],
and the role of intratumoral heterogeneity of PgR expres-
sion may complicate any associations observed between
lipoproteins and breast cancer prognosis. Thus, it would
have been interesting to quantify the gene expression of
PgR and look for associations with lipoproteins. However,
in present day routine diagnostics, intratumoral hetero-
geneity of PgR expression is not reported, which contrasts
with the present reporting of Ki67 in “hot spot” regions of
the tumor.
Given the increase in obesity and unfavorable metabolic
profiles worldwide, and the observed negative effect of
obesity on breast cancer development and prognosis [67],
there is a need for improved knowledge regarding the asso-
ciation between lipids and lipoproteins and breast cancer.
Metabolomics, studies of metabolites in organic matrices,
such as tissues and biofluids, as used in the present study,
may detect new biological associations, as the organism’s
metabolome may mirror disease impact [31]. This dynamic
is promising in breast cancer research toward the discovery
of new biomarkers of disease diagnosis, prognosis and
treatment response [31]. In addition, robust multivari-
ate statistical methods have been developed (PCA and
PLS), and applied to handle large amounts of metabolo-
mics data [42].
Conclusions
In conclusion, we observed in this small explorative hy-
pothesis generating study by using novel subfraction
NMR methodology, that Apo-A1, HDL and HDL subfrac-
tions’ contents of cholesterol, free cholesterol, phospho-
lipids, and Apo-A1 was associated with progesterone
receptor expression. No association was observed between
lipoproteins and ER expression, but we observed an
Table 4 Partial Least Square analysis (PLS); the association
between tumor characteristics and lipoprotein subfractions by
NMR
Tumor Characteristic β-coefficient p-value
Progesterone receptor, %
Total plasma Apolipoprotein A1, mg/dL 1.326 e-01 0.002
ILDL Free Cholesterol, mg/dL −6.625 e-03 0.062
ILDL Phospholipids, mg/dL −1.015 e-02 0.076
HDL Cholesterol, mg/dL 9.019 e-02 8.522 e-06
HDL Free Cholesterol, mg/dL 1.918 e-02 0.002
HDL Phospholipids, mg/dL 1.206 e-01 1.138 e-04
HDL Apolipoprotein A1, mg/dL 1.393 e-01 1.198 e-04
VLDL4 Cholesterol, mg/dL −1.227 e-02 0.068
VLDL4 Free Cholesterol, mg/dL −5.829 e-03 0.085
VLDL4 Phospholipids, mg/dL −1.138 e-02 0.056
HDL1 Cholesterol, mg/dL 4.957 e-02 0.014
HDL1 Phospholipids, mg/dL 6.670 e-02 0.012
HDL1 Apolipoprotein A1, mg/dL 7.637 e-02 0.022
HDL1 Apolipoprotein A2, mg/dL 7.235 e-03 0.041
HDL2 Free Cholesterol, mg/dL 3.600 e-03 0.040
HDL2 Phospholipids, mg/dL 2.240 e-02 0.009
HDL2 Apolipoprotein A1, mg/dL 2.479 e-02 0.012
HDL3 Phospholipids, mg/dL 2.549 e-02 0.011
HDL3 Apolipoprotein A1, mg/dL 2.906 e-02 0.016
Tumor grade 1–3
Total plasma Triglycerides, mg/dL −2.694 e-03 0.011
HDL Apolipoprotein A1, mg/dL −1.807 e-03 0.056
Ki67 %
HDL Cholesterol, mg/dL −3.252 e-02 0.060
HDL2 Cholesterol, mg/dL −7.904 e-03 0.083
Estrogen receptor, % No significant results
Nodal metastasis, no
PLS Partial Least Square (3 components included). Significance level p < 0.05
Abbreviations: HDL high-density lipoprotein, ILDL intermediar-low-density
lipoprotein, LDL low-density lipoprotein, VLDL very-low-density lipoprotein
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inverse association between the lipoprotein subfractions
HDL1 and Ki67 index, and very low-density lipoprotein
(VLDL) was positively associated with nodal metastasis.
Our findings suggesting that lipoprotein subfractions may
be associated with breast tumor characteristics, of import-
ance for tumor aggressiveness and prognosis, are sup-
ported by plausible biological mechanisms linking HDL
and apolipoproteins to breast cancer development and
prognosis. Our results are intriguing and encourage repli-
cations, but larger studies are needed, to define the clinical
implications of these findings.
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